MedTrace Logo

Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis

NCT01463371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-09-29

No results posted yet for this study

Summary

The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, the investigators will analyze the effect of long-term treatment with azithromycin (250 mg three times per week during three months) on airway oxidative stress markers in exhaled breath condensate of adult patients with stable non-CF bronchiectasis.

Conditions

Interventions

DRUG

Azithromycin

250 mg three times a week during three months

Sponsors & Collaborators

  • Sociedad Valenciana de Neumología

    collaborator UNKNOWN

  • Instituto de Investigacion Sanitaria La Fe

    lead OTHER

Principal Investigators

  • Alfredo De Diego Damia, MD · Instituto Investigación Sanitaria La Fe

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-04-30
Completion
2007-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01463371 on ClinicalTrials.gov